#ASH20: Gilead­'s Kite reads out PhII da­ta to back CAR-T play­er Yescar­ta in a new in­di­ca­tion

In its lat­est move in a CAR-T bat­tle against No­var­tis’ Kym­ri­ah, Gilead has read out Phase II da­ta to back three-year-old Yescar­ta in a po­ten­tial new in­di­ca­tion: re­lapsed/re­frac­to­ry in­do­lent non-Hodgkin’s lym­phoma.

Gilead be­came an overnight CAR-T leader when it bought Kite for $12 bil­lion back in 2017, snatch­ing up Yescar­ta in the process. It nabbed a quick OK in re­lapsed or re­frac­to­ry large B-cell lym­phoma two weeks lat­er — not long af­ter Kym­ri­ah be­came the world’s first ap­proved CAR-T ther­a­py. On Sept 4, Gilead an­nounced it had ap­plied for an sBLA in iNHL based on piv­otal Phase II da­ta from its Zu­ma-5 study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER